DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20181426

A retrospective study to evaluate the pattern of spontaneously reported antiretroviral induced adverse drug reactions in a tertiary care hospital

Swati V. Patil, Sudhir R. Pawar

Abstract


Background: To evaluate the adverse effect profile of spontaneously reported cases of adverse drug reactions due to antiretroviral (ART) drugs in a tertiary care teaching hospital.

Methods: A descriptive retrospective study of pattern of ART induced adverse drug reactions (ADRs) spontaneously reported to the Pharmacology department at a tertiary care hospital from January 2011 to December 2016. The details of suspected ADRs including drugs involved, treatment given for ADRs, and the outcome were also documented. These ADRs were analyzed for causality (WHO scale), severity (Hartwig et al. scale), seriousness (ICH E 2A guidelines), preventability (Schumock and Thornton scale) and type based on Edwards and Aronson classification system.

Results: Of the 75 cases of ART induced ADRs, reactions were slightly more common in males (52%) and had median age and duration of ART as 36 years and 109 days respectively. Drug induced anemia was the most common presentation followed by cutaneous ADR and zidovudine being the commonest offender. Severity was moderate in 85.3% and causality was probable in 16% and possible in 84% cases. The type reaction was augmented type in 41.3% and not preventable in 76%.

Conclusions: Zidovudine is the commonest drug implicated in causing anemia amongst the antiretrovirals. Spontaneous reporting method for antiretroviral pharmacovigilance is insufficient. Targeted spontaneous reporting or cohort event monitoring need to be studied for antiretroviral pharmacovigilance.


Keywords


Antiretrovirals, spontaneously reporting, Targeted spontaneous reporting

Full Text:

PDF

References


Nadkar MY, Bajpai S. Antiretroviral therapy: toxicity and adherence. J Assoc Physicians India. 2009;57:375-6.

Castelnuovo B, John L, Lutwama F, Roland A, Spacek LA. Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: Good virological response but high rate of toxicity. J Int Assoc Physicians AIDS Care (Chic). 2009;8:52-59.

Singh H, Dulhani N, Tiwari P, Singh P, Sinha T. A prospective, observational cohort study to elicit adverseeffects of antiretroviral agents in a remote resource-restricted tribal population of Chhattisgarh. Indian J Pharmacol. 2009;41(5):224-6.

Sharma A, Vora R, Modi M, Sharma A, Marfatia Y. Adverse effects of antiretroviral treatment. Indian J Dermatol Venereol Leprol. 2008;74:234-7.

Jena A, Sachdeva RK, Sharma A, Wanchu A. Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study. J Int Assoc Physicians AIDS Care (Chic). 2009;8(5):318-22.

Pattanapanyasat K, Thakar MR. CD4+T cell count as a tool to monitor HIV progression and anti-retroviral therapy. Indian J Med Res. 2005;121:539-49.

Kumarasamy N, Vallabhaneni S, Cecelia AJ, Yepthomi T, Balakrishnan P, Saghayam S, et al. Reasons for Modification of Generic Highly Active Antiretroviral Therapeutic Regimens Among Patients in Southern India. J Acquir Immune Defic Syndr. 2010;41:53-8.

Waller PC. Making the most of spontaneous adverse drug reaction reporting. Basic Clin Pharmacol Toxicol. 2006;98(3):320-3.

Rajesh R, Vidyasagar S, Patel N. Safety aspects of Antiretroviral therapy for management of HIV Infection. J basic clinical pharmacy. 2010;1(1):47-53.

Bhuvana KB, Hema NG, Sangeetha. A prospective observational study of adverse drug reactions to antiretroviral therapy: type and risk factors in a tertiary care teaching hospital. Int J Basic Clin Pharmacol. 2014;3:380-4.

Laurent C, Bourgeois A, Mpoudi-Ngole E, Ciaffi L, Kouanfack C, Mougnutou R, et al. Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon. AIDS research and human Retroviruses. 2008;24(3):393-400.

Rather ZA, Chowta MN, Prakash Raju GJ, Mubeen F. Evaluation of the adverse reactions of antiretroviral drug regimens in a tertiary care hospital. Indian J Pharmacol. 2013;45(2):145-8.

Masenyetse LJ, Manda SO, Mwambi HG. An assessment of adverse drug reactions among HIV positive patients receiving antiretroviral treatment in South Africa. AIDS Res Ther. 2015;12:6.

Agu KA, Oparah AC. Adverse drug reactions to antiretroviral therapy: Results from spontaneous reporting system in Nigeria. Perspectives Clinical Research. 2013;4(2):117-24.

Spaulding A, Rutherford GW, Siegfried N. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database Syst Rev. 2010;(10):CD008740.

Anwikar SR, Bandekar MS, Smrati B, Pazare AP, Tatke PA, Kshirsagar NA. HAART induced adverse drug reactions: a retrospective analysis at a tertiary referral health care center in India. Int J Risk Saf Med. 2011;23(3):163-9.

Mehta U, Durrheim DN, Blockman M, Kredo T, Gounden R, Barnes KI. Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br J Clin Pharmacol. 2008;65:396-406.

Sadiq S, Khajuria V, Tandon VR, Mahajan A, Singh JB. Adverse Drug Reaction Profile in Patients on Anti-tubercular Treatment Alone and in Combination with Highly Active Antiretroviral Therapy. J Clin Diagn Res. 2015;9(10):FC01-4.

Fletcher AP. Spontaneous adverse drug reaction reporting vs. event monitoring: A comparison. J R Soc Med. 1991;84:341-4.

Agu KA. Establishing pharmacovigilance system in a clinical setting. In: King RC, Oqua D, Agu KA, editors. GHAIN Pharmacovigilance for Antiretroviral Drugs Training for Healthcare professionals, Participants’ Manual. Silver Spring, MD: DAS, Incorporated; 2009:71-85.

Kalaiselvan V, Prasad T, Vivek D, Singh GN, Rathore A, Rewari B. Integration of National AIDS Control Program and Pharmacovigilance Program of India-Antiretroviral Drugs safety coactions in India. Int J AIDS Res. 2015;02(4):37-8.

Shanthi N, Chris D, Dennis F, Sten O. WHO Strategy for Collecting Safety Data in Public Health Programs, Complementing Spontaneous Reporting Systems. Drug Safety 2013;36(2):75-81.

Pal SN, Duncombe C, Falzon D, Olsson S. WHO strategy for collecting safety data in public health programmes: complementary spontaneous reporting systems. Drug Saf. 2013;36:75-81.

Rachlis B, Karwa R, Chema C, Pastakia S, Olsson S, Wools-Kaloustian K, et al. Targeted Spontaneous Reporting: Assessing Opportunities to Conduct Routine Pharmacovigilance for Antiretroviral Treatment on an International Scale. Drug Saf. 2016;39(10):959-76.